Clinical Scorecard: Evaluating CHA2DS2-VA and Non-CHA2DS2-VA Factors as Indicators of Mortality Following Cavotricuspid Isthmus Ablation: A Tool for Long-Term Risk Assessment

At a Glance

Key Highlights

• 27% of patients died during a mean follow-up of 1771 days.
• CHA₂DS₂-VA score ≥3 identified as optimal threshold for mortality prediction.
• Annual mortality rates: 1.4% for scores <3 vs. 9.9% for scores ≥3.
• CHA₂DS₂-VA score demonstrated good discriminative ability (c-index = 0.73).
• Pulmonary disease and obstructive sleep apnea independently predicted adverse long-term survival.

Guideline-Based Recommendations

Diagnosis

• CHA₂DS₂-VA score should be calculated at the time of ablation.

Management

• Incorporate CHA₂DS₂-VA and non-CHA₂DS₂-VA comorbidities for individualized follow-up strategies.

Monitoring & Follow-up

• Monitor patients post-ablation for long-term survival based on CHA₂DS₂-VA score.

Risks

• Higher CHA₂DS₂-VA scores correlate with increased mortality risk.

Patient & Prescribing Data

249 consecutive patients who underwent CTI ablation for typical AFL.

CHA₂DS₂-VA score can extend clinical utility beyond thromboembolic risk assessment.

Clinical Best Practices

• Utilize CHA₂DS₂-VA score for risk stratification in patients post-CTI ablation.
• Assess additional comorbidities for comprehensive risk evaluation.

Related Resources & Content

• European Society of Cardiology Guidelines